NR1H4 and metabolic dysfunction-associated steatohepatitis: Activation of hepatic FXR exerts beneficial effects on steatosis, inflammation, fibrosis and endothelial functions in the liver and could therefore be useful in the treatment of non-alcoholic steatohepatitis (NASH)19.